SAMe (S-Adenosyl Methionine)                                   SAMe article
     Is manufactured in the body but also made synthetically.      to order


SAMe alleviates all forms of Depression [many studies have confirmed that SAMe is more effective (approximately 15%) in the treatment of depression than antidepressants]. 
SAMe is especially effective in treating postpartum Depression.

SAMe counteracts the anxiety and depression commonly experienced by persons with drug dependence during detoxification [1,200 mg of SAMe per day significantly reduced the psychological stress encountered by former opiate users during their detoxification period].

AIDS patients have low cerebrospinal fluid levels of SAMe and for this reason SAMe is under investigation as a potential treatment for AIDS.

SAMe helps to protect against liver cancer in persons exposed to Liver carcinogens.
SAMe inhibits Alcohol-induced Liver damage. SAMe can prevent and cure cirrhosis.

SAMe (800 mg per day) alleviates Fibromyalgia [800 mg of SAMe per day had a significant reduction in the number of trigger points, reduction in fatigue, reduction in morning stiffness, and improvements in mood in Fibromyalgia patients].

SAMe improves Osteoarthritis.
Alzheimer's patients have severely decreased levels of SAMe within their brains.

SAMe is presently under investigation as a potential treatment for Parkinson's [Parkinson's patients have levels of SAMe that are only 60% of the levels of those of healthy subjects].

SAMe improves the ability of Neurotransmitters to bind to their receptor sites.
SAMe is an essential cofactor for the conversion of Norepinephrine to Adrenaline.

References

Bell, K. M., et al. S-adenosylmethionine treatment of depression: A controlled clinical trial. American Journal of Psychiatry. 145:1110-1114, 1988.

De Vanna, M., et al. Oral S-adenosyl-methionine in depression. Curr Ther Res. 52:478-485, 1992

Vahora, S. A., et al. S- adenosyl-methionine in depression. Neurosci Biobehav Rev. 12:139-141, 1988

Tavoni, A., et al. Evaluation of S-adenosylmethionine in primary fibromyalgia. Am. J. Med. 83 (Supplement 5A):107-110, 1987.

G. Stramentinoli (1987) "Pharmacologic aspects of [SAMe]" Am J Med 83 (suppl 5A), 35-42.

L. Morrison et al, (1996) "Brain [SAMe] levels are severely decreased in Alzheimer's disease" 
J Neurochem 67, 1328-31.

C. di Padova (1987) "[SAMe] in the treatment of osteoarthritis" Am J Med 83 (suppl 5A), 60-65.

B Konig (1987) "A long term (2 years) clinical trail with [SAMe] for the treatment of osteoarthritis" Am J Med 83, (suppl 5A), 89-94.

G. Vendemiale et al, (1989) "Effects of oral [SAMe] on hepatic glutathione.. liver disease" Scand J Gastroent 24, 407-14.

E. Reynolds et al, (1984) "Methylation and mood" Lancet II, 196-98.


L. Bonanomi & A. Gazzaniga (1980) "Toxicological, Pharmacokinetic and Metabolic Studies on Acetylcysteine" Eur J Repir Dis 61, 45-51.

A. Tavoni et al, (1987), "Evaluation of [SAMe] in Primary Fibromyalgia" Am J Med *3 (sippl 5A), 107-110.

K. McCully, The Homocysteine Revolution, New Canaan CT; Keats (1997).

O. Laudonno (1987) "Cytoprotective effect of [SAMe] compared with... Misoprostol against... gastric damage" Am J Med 83 (suppl 5A), 43-47.
I. Caruso & V. Pietrogrande (1987) " Comparing [SAMe], Naproxen and placebo in the treatment of degenerative joint disease" Am J Med 83 (suppl 5A), 66-71.

M. Frezza et al, (1988) "Prevention by [SAMe] of estrogen induced hepatobiliary toxicity in... women" Am J Gastroent 83, 1098-1102.

G. Vendemiale et al, (1989) "Effects of oral [SAMe] on hepatic glutathione.. liver disease" Scand J Gastroent 24, 407-14.

F. Corrales et al, (1991) "Inhibition of glutathione synthesis in the liver leads to [SAMe] synthetase reduction" Hepatol 14, 528-33.

B. Kagan et al, (1990) "Oral [SAMe] in depression: a... double-blind, placebo controlled trial" Am J Psychiat 147, 591-95.

C. Mathews & K. van Holde, Biochemistry, pp. 708-715, Redwood City, CA: Benjamin/ Cummings Pub. Co. (1990).